Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viagra Labeling To Include Cardiac Event And Priapism Warning

Executive Summary

Pfizer has updated labeling for Viagra (sildenafil) to include postmarketing reports of adverse events and discussion of the effect of sexual activity with Viagra on cardiovascular safety.

You may also be interested in...



FDA Safety Website Has Risks Of Its Own, Pfizer CEO Warns

Pfizer is concerned that FDA's plan to publicize emerging safety issues with drugs will lead to sensationalized and counterproductive media coverage

FDA Safety Website Has Risks Of Its Own, Pfizer CEO Warns

Pfizer is concerned that FDA's plan to publicize emerging safety issues with drugs will lead to sensationalized and counterproductive media coverage

Pfizer Viagra PR Model: Patient-Physician Relationship Is Focus

Pfizer's focus on reinforcing the patient-physician relationship in its communications for Viagra (sildenafil) should serve as a model for future "social blockbusters," Pfizer Senior Medical Advisor Michael Magee, MD, suggested

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel